Skip to main content
SpringerLink
Log in
Book cover

Biomedical Applications of Acridines pp 5–8Cite as

Nomenclature

  • Chapter
  • First Online:

  • 545 Accesses

Part of the book series: Progress in Drug Research ((PDR,volume 72))

Abstract

Acridines have been known since 1870. Thus, their nomenclature has developed for long time. There are many numbering systems from which we have selected two most important ones. Moreover, plenty of trivial names exist and one has to be very careful when searching in the information databases.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Graebe, C., Caro, H.: Ueber Acridin. Ber. Dtsch. Chem. Ges. 3(2), 746–747 (1870)

    Google Scholar 

  2. Duegan, B.S., Narang, K.S., Ray, J.N.: Acridine derivatives. Part II. J. Chem. Soc. pp. 476–478 (1939)

    Google Scholar 

  3. Dupre, D.J., Robinson, F.A.: N-Substitued 5-aminoacridines. J. Chem. Soc. 549–551 (1945)

    Google Scholar 

  4. Albert, A.: The Acridines: Their Preparation, Physical, Chemical, and Biological Properties and Uses. Richard Clay and Company Ltd, Bungay, Suffolk, GB (1951)

    Google Scholar 

  5. Acheson, R.M.: Nomenclature and Numbering System, 2 edn., chap. 1, pp. 1–8. John Wiley & Sons, Inc., New York, London, Sydney, Toronto (1973)

    Google Scholar 

  6. Demeunynck, M., Charmantray, F., Martelli, A.: Interest of acridine derivatives in the anticancer chemotherapy. Curr. Pharm. Des. 7, 1703–1724 (2001)

    Article  CAS  Google Scholar 

  7. Šebestík, J., Hlaváček, J., Stibor, I.: A role of the 9-aminoacridines and their conjugates in a life science. Curr. Protein Pept. Sci. 8(5), 471–483 (2007)

    Google Scholar 

  8. Salem, O., Vilkova, M., Plsikova, J., Grolmusova, A., Burikova, M., Prokaiova, M., Paulikova, H., Imrich, J., Kozurkova, M.: DNA binding, anti-tumour activity and reactivity toward cell thiols of acridin-9-ylalkenoic derivatives. J. Chem. Sci. 127(5), 931–940 (2015)

    Article  CAS  Google Scholar 

  9. Graebe, C., Lagodzinski, K.: Ueber Acridon. Justus Liebigs Ann. Chem. 276(1), 35–53 (1893)

    Google Scholar 

  10. Wadkins, R.M., Graves, D.E.: Thermodynamics of the interactions of m-AMSA and o-AMSA with nucleic acids: influence of ionic strength and DNA base composition. Nucl. Acids Res. 17(23), 9933–9946 (1989)

    Google Scholar 

  11. Gamage, S., Figgitt, D., Wojcik, S., Ralph, R., Ransijn, A., Mauel, J., Yardley, V., Snowdon, D., Croft, S., Denny, W.: Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1’-substituted 9-anilinoacridines. J. Med. Chem. 40(16), 2634–2642 (1997)

    Article  CAS  Google Scholar 

  12. Robertson, I.G., Palmer, B.D., Paxton, J.W., Shaw, G.J.: Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. Xenobiotica 22, 657–669 (1992)

    Article  CAS  Google Scholar 

  13. Ehsanian, R., Van Waes, C., Feller, S.M.: Beyond DNA binding - a review of the potential mechanisms mediating quinacrine’s therapeutic activities in parasitic infections, inflammation, and cancers. Cell. Commun. Signal. 9, art. no. 13 (2011)

    Google Scholar 

  14. Gracon, S.I., Knapp, M.J., Berghoff, W.G., Pierce, M., DeJong, R., Lobbestael, S.J., Symons, J., Dombey, S.L., Luscombe, F.A., Kraemer, D.: Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis. Assoc. Disord. 12, 93–101 (1998)

    Article  CAS  Google Scholar 

  15. Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowsky, C.H., Dolan-Ureno, J.: A controlled trial of tacrine in Alzheimer’s disease. J. Am. Med. Assoc. 268(18), 2523–2529 (1992)

    Article  CAS  Google Scholar 

  16. Knapp, M.J., Knopman, D., Solomon, P.R., Pendlebury, W.W., Davis, C.S., Gracon, S.I., Apter, J.T., Lazarus, C.N., Baker, K.E., Barnett, M., Baumel, B., Eisner, L.S., Bennett, D., Forchetti, C., Levin, A., Blass, J.P., Nolan, K.A., Gaines, E.R., Relkin, N., Borison, R.L., Diamond, B., Celesia, G.G., Ross, A.P., Dexter, J., Doody, R., Lipscomb, L., Kreiter, K., DuBoff, E.A., Block, P., Marshall, D., Westergaard, N., Earl, N.L., Wyne, S.V., Hinman-Smith, E., Farlow, M., Hendrie, H.C., Caress, J.A., Farmer, M., Harper, J.E., Ferguson, J., Foster, N.L., Barbas, N.R., Bluemlein, L.A., Gelb, D.J., Berent, S., Giordani, B., Greenwald, M., Bergman, S., Roger, L.F., Groenendyk, A., Wood, M., Jurkowski, C., Katz, I., Doyle, S., Smith, B.D., Kellner, C., Bernstein, H.J., Bachman, D.L., Deinard, S., Langley, L., Bridges, S., Margolin, R.A., Burger, M.C., Wiser, S.L., Crenshaw, C., Morris, J.C., Rubin, E.H., Coats, M.A., Reyes, P.F., Bentz, C., Doyle, L.L., Rymer, M.M., Bettinger, I.E., Laubinger, M.P., Sadowsky, M.C.H., Martinez, W., Zuniga, J., Stone, R., Winner, P., Maté, L., Lessard, C., Schneider, L., Pawluczyk, S., Smith, W.T., Losk, S.N., Marambe, L., Groccia-Ellison, M.E., Edwards, K.R., Taylor, J., Calabrese, V.P., Harkins, S.W., Thein, Stephen G., J., Dewar, J.A., Williams, G., Drennan, C., Tuttle, P., Principi, N., Ford, E.M., Tyndall, R.J., Kelley, C.K.: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. J. Am. Med. Assoc. 271(13), 985–991 (1994)

    Google Scholar 

  17. Butterfield, D., Hensley, K., Hall, N., Umhauer, S., Carney, J.: Interaction of tacrine and velnacrine with neocortical synaptosomal membranes: Relevance to Alzheimer’s-disease. Neurochem. Res. 18(9), 989–994 (1993)

    Article  CAS  Google Scholar 

  18. Braga, M.F., Harvey, A.L., Rowan, E.G.: Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro. Br. J. Pharmacol. 102, 909–915 (1991)

    Article  CAS  Google Scholar 

  19. Gniazdowski, M., Szmigiero, L.: Nitracrine and its congeners - an overview. Gen. Pharmacol. 26(3), 473–481 (1995)

    Article  CAS  Google Scholar 

  20. Chufan, E.E., Kapoor, K., Ambudkar, S.V.: Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein. Biochem. Pharmacol. 101, 40–53 (2016)

    Article  CAS  Google Scholar 

  21. Kettle, A.J., Robertson, I.G., Palmer, B.D., Anderson, R.F., Patel, K.B., Winterbourn, C.C.: Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase. Biochem. Pharmacol. 44, 1731–1738 (1992)

    Article  CAS  Google Scholar 

  22. Afzal, A., Sarfraz, M., Wu, Z., Wang, G., Sun, J.: Integrated scientific data bases review on asulacrine and associated toxicity. Crit. Rev. Oncol. Hematol. 104, 78–86 (2016)

    Article  Google Scholar 

  23. Caponigro, F., Dittrich, C., Sorensen, J.B., Schellens, J.H.M., Duffaud, F., Paz Ares, L., Lacombe, D., de Balincourt, C., Fumoleau, P.: Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur. J. Cancer 38, 70–74 (2002)

    Article  CAS  Google Scholar 

  24. Dittrich, C., Coudert, B., Paz-Ares, L., Caponigro, F., Salzberg, M., Gamucci, T., Paoletti, X., Hermans, C., Lacombe, D., Fumoleau, P.: European organization for research and treatment of cancer-early clinical studies group/new drug development programme (EORTC-ECSG/NDDP): phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer. Eur. J. Cancer 39, 330–334 (2003)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academy of Sciences, Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic

    Jan Ježek, Jan Hlaváček & Jaroslav Šebestík

Authors
  1. Jan Ježek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Hlaváček
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaroslav Šebestík
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaroslav Šebestík .

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Ježek, J., Hlaváček, J., Šebestík, J. (2017). Nomenclature. In: Biomedical Applications of Acridines . Progress in Drug Research, vol 72. Springer, Cham. https://doi.org/10.1007/978-3-319-63953-6_2

Download citation

Publish with us

Policies and ethics

Search

Navigation